Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor’s office. Ikarovec’s IKAR-003 is currently in preclinical ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by working to bring to market three treatments for blindness-related diseases, two ...

Shares of Krystal Biotech KRYS gained 3.9% yesterday after the company announced that it had dosed the first patient in a phase I/II study evaluating its eye drop KB801 for the treatment of ...

Sanofi said its gene therapy to treat neovascular age-related macular degeneration was approved for fast-track development in the U.S. The biopharmaceutical company said Thursday that the Food and ...

Under the merger terms, Eli Lilly will launch a tender offer to acquire all outstanding Adverum shares for up to $12.47 per share, consisting of $3.56 in cash at closing and a non-transferable ...

Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to explore a new way to treat vision loss using gene therapy. The research could ...